ERBB2 and cancer: Moreover, anti-CA125, anti-HER2/neu, anti-MUC1, anti-EGFR mAb treatment can circumvent the tolerance to self-antigens expressed on tumor cells as shown by the increase of the frequency of CD4+ and/or CD8+ T cells recognizing peptides derived from the target molecule in cancer patients [47–51].